| 李月,冯佳丽,王霁.脾氨肽联合布地奈德治疗过敏性鼻炎病儿的效果及对外周血辅助性 T细胞 17/调节性 T细胞平衡和相关细胞因子水平的影响[J].安徽医药,2025,29(10):2096-2100. |
| 脾氨肽联合布地奈德治疗过敏性鼻炎病儿的效果及对外周血辅助性 T细胞 17/调节性 T细胞平衡和相关细胞因子水平的影响 |
| Effect of spleen aminopeptide combined with budesonide in the treatment of allergic rhinitis in children and its impact on peripheral blood Th17/Treg balance and related cytokine levels |
| |
| DOI：10.3969/j.issn.1009-6469.2025.10.037 |
| 中文关键词: 鼻炎，过敏性 脾氨肽 布地奈德 辅助性 T细胞 17 调节性 T细胞 |
| 英文关键词: Rhinitis, allergic Spleen Aminopeptide Budesonide Helper T cells 17 Regulatory T cells |
| 基金项目: |
|
| 摘要点击次数: 33 |
| 全文下载次数: 42 |
| 中文摘要: |
| 目的观察脾氨肽联合布地奈德治疗过敏性鼻炎病儿的效果并分析其对外周血辅助性 T细胞 17(Th17)/调节性 T细胞(Treg)平衡及相关细胞因子水平的影响。方法选取 2020年 10月至 2021年 10月河南省职工医院收治的 126例过敏性鼻炎病儿作为研究对象，按随机数字表法分为两组。对照组 63例给予布地奈德鼻喷雾剂治疗，联合组 63例采用脾氨肽口服溶液联合布地奈德鼻喷雾剂治疗，均治疗 3个月。观察治疗前后临床症状变化、 Th17/Treg、血清白细胞介素 -6(IL-6)、白细胞介素 -17(IL-17)、转化生长因子 -β1(TGF-β1)水平及疗效，对比两组不良反应发生情况。结果与治疗前相比，治疗后两组各剂型亚组临床症状评分、 Th17比例、 Th17/Treg、IL-6、IL-17水平均降低( P<0.05)；联合组各剂型亚组临床症状评分、 Th17比例、 Th17/Treg、IL-6、 IL-17水平均低于对照组( P<0.05)。治疗后联合组片剂亚组 IL-6水平为( 107.59±12.38)ng/L低于对照组片剂亚组的( 129.43±13.87)ng/L(P<0.05)。与治疗前相比，治疗后两组各剂型亚组 Treg比例、 TGF-β1水平均升高( P<0.05)；联合组各剂型亚组 Treg细胞比例、 TGF-β1水平均高于对照组( P<0.05)。联合组总有效率为 93.65%高于对照组的 80.95%(P<0.05)；两组各剂型亚组不良反应发生情况比较差异无统计学意义( P>0.05)。结论脾氨肽联合布地奈德治疗有助于缓解过敏性鼻炎病儿症状，调节外周血 Th17/Treg平衡和相关细胞因子水平，疗效好且安全。 |
| 英文摘要: |
| Objective To observe the efficacy of Spleen Aminopeptide combined with budesonide in the treatment of allergic rhinitisin children and to analyze its impact on the balance of peripheral blood helper T cell 17 (Th17) / regulatory T cell (Treg) and related cy-tokine levels.Methods One hundred and twenty-six children with allergic rhinitis treated in Staff Hospital of He'nan Province fromOctober 2020 to October 2021 were randomly divided into two groups. 63 cases in the control group were treated with budesonide nasalspray, while 63 cases in the combined group were treated with Spleen Aminopeptide Oral Solution combined with budesonide nasalspray, and both groups were treated for 3 months. The changes of clinical symptoms, Th17/Treg, serum interleukin-6 (IL-6), interleukin-17 (IL-17) and transforming growth factor-β1 (TGF-β1) level, and curative effect were observed before and after treatment. The adverse reactions of the two groups were compared.Results Compared with before treatment, the clinical symptom scores, Th17 ratio, Th17/ Treg, IL-6, and IL-17 levels of each dosage form subgroup in both groups decreased after treatment (P < 0.05). The clinical symptom scores, Th17 ratio, Th17/Treg, IL-6, and IL-17 levels of each dosage form subgroup in the combined group were lower than those in the control group (P < 0.05). After treatment, the IL-6 level in the combination group tablet subgroup was (107.59 ± 12.38) ng/L, lower thanthat in the control group tablet subgroup (129.43±13.87) ng/L (P < 0.05). Compared with before treatment, the Treg ratio and TGF-β1 levels in each subgroup of both groups increased after treatment (P < 0.05). The proportion of Treg cells and TGF-β1 levels in each sub-group of the combined group were higher than those in the control group (P < 0.05). The total effective rate of the combined group was 93.65%, which was higher than the 80.95% of the control group (P < 0.05). There was no statistically significant difference in the occur-rence of adverse reactions between the two subgroups of each dosage form (P > 0.05).Conclusion The treatment of Spleen Aminopep-tide combined with budesonide is helpful to alleviate the symptoms of children with allergic rhinitis, regulate the balance of Th17/Tregin peripheral blood and the level of related cytokines, which is effective and safe. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
